We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Doximity (DOCS - Free Report) ended the recent trading session at $26.52, demonstrating a +1.22% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.17% for the day. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
Coming into today, shares of the medical social networking site had lost 1.91% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 lost 0.24%.
The investment community will be paying close attention to the earnings performance of Doximity in its upcoming release. In that report, analysts expect Doximity to post earnings of $0.34 per share. This would mark a year-over-year decline of 24.44%. Our most recent consensus estimate is calling for quarterly revenue of $170.66 million, up 1.27% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.33 per share and revenue of $675.74 million, indicating changes of -12.5% and +4.79%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Doximity is currently sporting a Zacks Rank of #4 (Sell).
Digging into valuation, Doximity currently has a Forward P/E ratio of 19.64. This indicates a discount in contrast to its industry's Forward P/E of 30.37.
We can also see that DOCS currently has a PEG ratio of 11.42. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. DOCS's industry had an average PEG ratio of 3.08 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Doximity (DOCS) Gains As Market Dips: What You Should Know
Doximity (DOCS - Free Report) ended the recent trading session at $26.52, demonstrating a +1.22% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.17% for the day. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
Coming into today, shares of the medical social networking site had lost 1.91% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 lost 0.24%.
The investment community will be paying close attention to the earnings performance of Doximity in its upcoming release. In that report, analysts expect Doximity to post earnings of $0.34 per share. This would mark a year-over-year decline of 24.44%. Our most recent consensus estimate is calling for quarterly revenue of $170.66 million, up 1.27% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.33 per share and revenue of $675.74 million, indicating changes of -12.5% and +4.79%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Doximity is currently sporting a Zacks Rank of #4 (Sell).
Digging into valuation, Doximity currently has a Forward P/E ratio of 19.64. This indicates a discount in contrast to its industry's Forward P/E of 30.37.
We can also see that DOCS currently has a PEG ratio of 11.42. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. DOCS's industry had an average PEG ratio of 3.08 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.